Examining the Concordance of Patient Age Distribution between Genitourinary (GU) Clinical Trials and Real-World Disease Populations: Kidney, Prostate and Bladder Cancer Analysis

Although individuals over 70 years of age share a larger burden of cancer prevalence and medication use, older adults are significantly underrepresented in clinical research.¹ Specifically, those older than 75 years of age comprised < 8% of participants in clinical studies from 2005 to 2015.² Individuals diagnosed with urological cancers represent an older age group, exhibiting median diagnosis ages of 67 years for prostate cancer, 64 years for kidney cancer, and 73 years for bladder cancer.^3,4 As a result, there is a potential mismatch between the actual patient age distribution in the real world (disease age prevalence) and that represented in genitourinary (GU) clinical trials, which may result in skewed outcomes based on the data from these trials. This study was designed to track and analyze changes in the median age of participants across kidney, bladder, and prostate cancers in clinical trials over time, and to compare these findings with actual disease demographics. …